This phase 2 randomized clinical trial examines the treatment regimen of mFOLFOXIRI plus cetuximab followed by either cetuximab or bevacizumab for patients with RAS and BRAF wild-type metastatic colorectal cancer.
http://ift.tt/2EsF0iB
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου